Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
Kerr RS., Love S., Segelov E., Johnstone E., Falcon B., Hewett P., Weaver A., Church D., Scudder C., Pearson S., others .